Development and validation of HPLC‐ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium

Author:

Wang Xiaoming1ORCID,Patrikeeva Svetlana1,Nanovskaya Tatiana1,Bryant Valentina1

Affiliation:

1. Maternal‐Fetal Pharmacology and Bio‐Development Laboratories, Department of Obstetrics & Gynecology University of Texas Medical Branch Galveston Texas USA

Abstract

AbstractA simple and reliable HPLC‐ultraviolet (HPLC‐UV) method was developed and validated for the quantification of pritelivir in the samples of medium from the experiments utilizing the ex vivo technique of dual perfusion of the human placental lobule. Phenacetin was used as an internal standard (IS) in our HPLC‐UV method. Chromatographic separation of pritelivir and phenacetin was achieved on a Waters Symmetry C18 HPLC column (100 × 2.1 mm, 3.5 μm) at ambient temperature (22–25°C). The mobile phase was composed of 50% methanol in deionized water (v/v), the flow rate for isocratic elution was established at 0.25 mL/min, and the detection wavelength for pritelivir and IS was set at 254 nm. Pritelivir and IS were extracted with the protein precipitation method using methanol as a solvent. The calibration curve for pritelivir exhibited linearity (r2 > 0.99) within the concentration range from 0.155 to 6.62 μg/mL. Within‐ and between‐day accuracy ranged from 97% to 110% with relative standard deviation (RSD) values not exceeding 10%. The extraction recovery of pritelivir and IS ranged from 89% to 91% with RSD not exceeding 7%. Pritelivir was stable under the storage and sample handling conditions. This validated HPLC‐UV method was utilized to quantify pritelivir in the placental perfusion medium samples, and the resulting concentrations were authenticated with incurred sample reanalysis to confirm the reliability of the method.

Funder

Foundation for the National Institutes of Health

Publisher

Wiley

Reference19 articles.

1. AiCuris(2020).AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients. [Press Release] June 5 2020.https://www.aicuris.com/index.php/fuseaction/download/lrn_file/200604_aicuris_press-release_pritelivir_fda-break-through.pdf

2. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods

3. Hydrolysis of sulphonamides in aqueous solutions

4. Pharmacokinetics-Pharmacodynamics of the Helicase-Primase Inhibitor Pritelivir following Treatment of Wild-Type or Pritelivir-Resistant Virus Infection in a Murine Herpes Simplex Virus 1 Infection Model

5. Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3